Feasibility and Safety of a Combined Metabolic Strategy in Glioblastoma Multiforme: A Prospective Case Series

Table 1

Patient demographic, physical, and tumour characteristics at the time of commencing the combined metabolic strategy.

Characteristic	Patients (n = 10)
Demographic
Age (years)	58.0 +/−11.9 (range, 40–74)
Gender (male)	7 (70%)
Ethnicity
European	9 (90%)
Asian	1 (10%)
Previous cancer diagnosis
Breast cancer	2 (20%)
Fibromyxoid sarcoma	1 (10%)
Physical
Body weight (kg)	75.1 +/−13.8
Body mass index	25.4 +/−4.3
Function (ECOG performance status score)
0	3 (30%)
1	5 (50%)
2	2 (20%)
Tumour
Location (bulk of tumour)
Temporal	4
Frontal	2
Thalamus and brainstem	2
Parietal	1
Occipital	1
Growth status
Relatively recent diagnosis (serial imaging not yet obtained)	5 (50%)
No progression (no tumour recurrence postresection)	3 (30%)
Progression (tumour recurrence postresection)	2 (10%)
MGMT promoter methylation status
Unmethylated	3 (30%)
Methylated	5 (50%)
Unknown	2 (20%)
IDH 1 mutation status
Negative	9 (90%)
Positive	0
Unknown	1 (10%)

Except for % variables, values are presented as mean +/−standard deviation. ECOG—eastern cooperative oncology group; MGMT—O6-methylguanine-DNA-methyltransferase; IDH 1—isocitrate dehydrogenase 1.